TG4070 – Phase 1 trial: Evaluation in Combination with Nivolumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients
TG4070
TG4070 is the second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate derived from our proprietary myvac® platform, expanding into non-small cell lung cancer (NSCLC). TG4070 is being evaluated in a Phase 1 trial in combination with nivolumab in patients with resected NSCLC following neoadjuvant nivolumab plus chemotherapy.
Discover TG4070
Phase 1: Safety and Tolerability
Key news
about Phase 1
Download the Press Release
Watch the replay of our KOL event
* please accept targeting cookies to allow replay
Despite advances in perioperative immunotherapy, approximately 65% of patients with NSCLC do not achieve a major pathological response* and remain at high risk of relapse.
TG4070 is designed for this high-risk population, with the potential to enhance and sustain anti-tumor immune responses when combined with checkpoint inhibitors.
*Disappearance of at least 90% of tumor cells
TG4070: Combining Transgene’s Proprietary AI-driven, Platform and Manufacturing Expertise
SNIPER
- TG4070 is powered by SNIPER (Specific Neoantigen Identification and Prediction of Elicited Response) Transgene’s proprietary AI-driven bioinformatics tool designed to identify and prioritize highly immunogenic neoantigens helping focus the INTV on the most relevant tumor-specific targets.
VacDesignR ®
- Fully integrated to myvac®, VacDesignR plays a key role in the design of myvac® candidates. Fully internalized, this bioinformatics tool enables optimization of the integration of the 30 selected neoantigens and helps improve both vaccine candidate design and the efficiency of recombinant viral vector production within the myvac® platform.
Cell line manufacturing
TG4070 is based on Transgene’s MVA (Modified Vaccinia Ankara) vector and is engineered to encode patient-specific neoantigens identified using SNIPER, Transgene’s proprietary neoantigen AI-driven selection tool. It is produced using a scalable cell line manufacturing process, designed to support robust and reliable supply.
Additional ressources
Key presentation
Latest press releases

- November 9, 2026Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
- September 24, 2026Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
- September 8, 2026Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
- June 22, 2026Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
- April 13, 2026Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
- January 9, 2026Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
- November 6, 2025Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
- October 3, 2025Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
- September 16, 2025Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
- June 19, 2025Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer